trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['bcsm']
 just published nejm. practice changing (and her2+redefining) data. patients w/hr+ her2low tx w/t-dxd overall survival 23.9 months vs 17.5 months physicians choice groups. pfs 10.1 vs 5.4 months. #asco22 #bcsm #her2low 
??Oncologist|??Cancer Researcher|President Ky @ASCO|MedSchool Professor @UofL|Faculty @ASCO @NCCN @OncoAlert|Advisor @MedScape @Onclive @Doximity|#MedTwitter